Day: August 12, 2025

– Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference in Q4 2025 – Phase 2 ASPEN-Breast evorpacept trial design updated to enable CD47 and HER2 biomarker-driven strategy in a single-arm study; anticipated interim data readout in Q3 2026 – ALX2004 Phase 1 clinical trial remains on track to enroll first patient in August – Focus on driving ASPEN-Breast and ALX2004 data milestones within the cash runway, now extended into Q1 2027 – Appoints Daniel Curran, M.D. to the Board of Directors – Company to host webcast Tuesday, August 12 at 1:30 p.m. PT/4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO),...

Muzastotug (ADG126) Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached Alignment with FDA on Phase 2 and Phase 3 trial design elements. Company expects to begin enrolling patients in Phase 2 in 2H 2025 SAFEbody option exercised and up to US$25 million strategic investment by Sanofi, with cash runway extended into 2027 Sanofi will conduct a Phase 1b/2 trial in combination with ADG126 in over 100 patients Strengthened leadership team with key additions Partnered with ConjugateBio for development of bispecific ADCs SAN DIEGO and SUZHOU, China, Aug. 12, 2025 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based...

Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphoma Initiated the PiNACLE pivotal trial of LYL314 in patients with large B-cell lymphoma receiving treatment in the third‑ or later-line (3L+) setting; remain on track to initiate a pivotal trial in the second-line (2L) setting by early 2026 Entered into a securities purchase agreement for a private placement for gross proceeds of up to approximately $100 million Pro-forma cash of approximately $347 million inclusive of the initial proceeds from the private placement to support advancing pipeline into mid-2027 through key clinical milestonesSOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage...

Electromagnetic Geoservices ASA’s (“EMGS” or the “Company”) financial report and market presentation for the second quarter of 2025 are attached. Summary: * The Company recorded revenues of USD 9.6 million, down from USD 13.8 million in the second quarter of 2024 and down from USD 10.0 million in the first quarter of 2025. * Adjusted EBITDA (including capitalised multi-client expenses and vessel and office lease expenses) of USD 2.1 million, down from USD 7.0 million in the second quarter of 2024. * Free cash decreased with USD 2.5 million during the quarter, to USD 3.5 million. * During the quarter, the Atlantic Guardian completed the second of two proprietary acquisitions in India. A pre-recorded presentation will be available over the internet from 21:00 (local time Norway) today. To access the presentation, please go to the Company’s...